Baldwin Wealth Partners LLC MA Sells 790 Shares of ResMed Inc. (NYSE:RMD)

Baldwin Wealth Partners LLC MA lowered its stake in ResMed Inc. (NYSE:RMD) by 13.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,297 shares of the medical equipment provider’s stock after selling 790 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in ResMed were worth $1,211,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sei Investments Co. increased its holdings in ResMed by 68.1% during the 2nd quarter. Sei Investments Co. now owns 36,501 shares of the medical equipment provider’s stock worth $6,987,000 after purchasing an additional 14,793 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of ResMed by 74.1% in the 2nd quarter. Public Sector Pension Investment Board now owns 5,632 shares of the medical equipment provider’s stock valued at $1,078,000 after buying an additional 2,398 shares during the last quarter. AQR Capital Management LLC lifted its stake in ResMed by 20.6% in the second quarter. AQR Capital Management LLC now owns 172,783 shares of the medical equipment provider’s stock valued at $33,074,000 after acquiring an additional 29,538 shares during the last quarter. MBB Public Markets I LLC bought a new position in ResMed during the second quarter worth about $2,017,000. Finally, Mackenzie Financial Corp boosted its stake in shares of ResMed by 13.6% during the 2nd quarter. Mackenzie Financial Corp now owns 167,155 shares of the medical equipment provider’s stock worth $31,997,000 after acquiring an additional 19,995 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Trading Up 1.3 %

NYSE RMD opened at $253.69 on Monday. ResMed Inc. has a twelve month low of $170.56 and a twelve month high of $260.49. The business’s fifty day moving average is $239.25 and its 200 day moving average is $235.01. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The company has a market cap of $37.24 billion, a price-to-earnings ratio of 33.56, a price-to-earnings-growth ratio of 1.78 and a beta of 0.70.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same period in the previous year, the business posted $1.64 earnings per share. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. As a group, sell-side analysts expect that ResMed Inc. will post 9.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total transaction of $491,300.00. Following the completion of the transaction, the director now directly owns 81,218 shares of the company’s stock, valued at $19,951,201.70. This trade represents a 2.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $243.09, for a total value of $1,497,434.40. Following the transaction, the insider now directly owns 21,718 shares in the company, valued at $5,279,428.62. The trade was a 22.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,099 shares of company stock worth $2,719,385 in the last ninety days. Company insiders own 0.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RMD. Stifel Nicolaus started coverage on shares of ResMed in a research note on Friday, December 13th. They set a “hold” rating and a $250.00 target price for the company. Royal Bank of Canada increased their price target on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a report on Friday, October 25th. The Goldman Sachs Group began coverage on shares of ResMed in a research report on Thursday, January 16th. They set a “buy” rating for the company. Finally, Robert W. Baird raised their target price on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ResMed has an average rating of “Moderate Buy” and a consensus target price of $238.40.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.